Specific protection of folate reductase against chemical and proteolytic inactivation.
D000818:Animals; D002268:Carboxypeptidases / Q000494:pharmacology*; D002729:Chloromercuribenzoates / Q000494:pharmacology*; D002918:Chymotrypsin / Q000494:pharmacology; D005029:Ethylenediamines / Q000494:pharmacology*; D005971:Glutamates / Q000494:pharmacology; D007461:Iodoacetates / Q000494:pharmacology*; D007931:Leucyl Aminopeptidase / Q000494:pharmacology; D008727:Methotrexate / Q000378:metabolism*; D010447:Peptide Hydrolases / Q000494:pharmacology*; D010618:Phenanthrolines / Q000494:pharmacology*; D011687:Purines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D012510:Sarcoma 180 / Q000378:metabolism*; D013696:Temperature; D013762:Tetrahydrofolate Dehydrogenase / Q000378:metabolism*; D014357:Trypsin / Q000494:pharmacology*
D002729:Chloromercuribenzoates; D005029:Ethylenediamines; D005971:Glutamates; D007461:Iodoacetates; D010618:Phenanthrolines; D011687:Purines; D011743:Pyrimidines; D013762:Tetrahydrofolate Dehydrogenase; D002268:Carboxypeptidases; D010447:Peptide Hydrolases; D007931:Leucyl Aminopeptidase; D002918:Chymotrypsin; D014357:Trypsin; D008727:Methotrexate